novartis ag-adr (NOTA:Frankfurt)
novartis ag-adr (NOTA) Snapshot
|
Open
€58.31
|
Previous Close
€57.77
|
|
|
Day High
€58.31
|
Day Low
€57.19
|
|
|
52 Week High
05/15/13 - €58.97
|
52 Week Low
05/24/12 - €40.50
|
|
|
Market Cap
--
|
Average Volume 10 Days
684.8
|
|
|
EPS TTM
--
|
Shares Outstanding
0.0
|
|
|
EX-Date
02/26/13
|
P/E TM
--
|
|
|
Dividend
€2.39
|
Dividend Yield
3.22%
|
novartis ag-adr (NOTA) Related Businessweek News
novartis ag-adr (NOTA) Details
Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism, respiratory, and other medicines. The company’s Alcon division provides various eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates, primarily antibiotics; protein or biotechnology-based products; cytotoxic products for the hospital market; and biotech manufacturing services to other companies. The company’s Vaccines and Diagnostics division provides preventive human vaccines, and blood testing and molecular diagnostics products to prevent the spread of infectious diseases. Its Consumer Health division consists of two divisions, including over-the-counter medicines that offer readily available consumer medicines; and Animal Health, which provides veterinary products for farm and companion animals. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
novartis ag-adr (NOTA) Top Compensated Officers
novartis ag-adr (NOTA) Key Developments
Oxford BioMedica plc announced that it has signed an agreement with Novartis to manufacture clinical grade material utilising Oxford BioMedica's LentiVector® gene delivery technology. Under the terms of the agreement, Oxford BioMedica will also provide certain process development services and expects to receive between £2.5 million and £4 million from Novartis over the next 12 months. Oxford BioMedica will be responsible for manufacturing several batches of a lentiviral vector encoding CTL019 technology. This vector will be used to transduce patients' immune cells (T-cells) in an ex vivo process before they are re-infused into patients. CTL019 targets a protein called CD19 that is associated with a number of B-cell malignancies including chronic lymphocytic leukemia, B-cell acute lymphocytic leukaemia and diffuse large B-cell lymphoma.
The city of Chicago is among the local governments named as plaintiff in a lawsuit accusing the Novartis of paying kickbacks to doctors. It's the second civil fraud suit the federal government has launched against the company in a week. The first accuses the company of paying kickbacks to pharmacies to use one of its drugs in exchange for discounts and rebates. The suit alleges that the scheme resulted in Medicare and Medicaid paying millions of dollars in reimbursements. In this second suit, the federal government, 27 states, New York City, the District of Columbia, and Chicago said doctors were paid many millions of dollars to speak about the company drugs, but often did not perform any educational duties at all.
Novartis AG announced it would cut 300 jobs at its US plant in Lincoln, Nebraska, where authorities had detected quality problems.
| Recently Viewed | |||
| NOTA:GR | €57.73 EUR | -0.037 | |
| Company | Last | Change |
| Johnson & Johnson | $88.46 USD | -0.13 |
| Nestle SA | SFr.67.35 CHF | +0.40 |
| Pfizer Inc | $29.30 USD | +0.52 |
| Procter & Gamble Co/The | $78.82 USD | +0.02 |
| Roche Holding AG | SFr.258.50 CHF | +7.50 |
| View Industry Companies | ||
Industry Analysis
NOTA
Industry Average
| Valuation | NOTA | Industry Range |
| Price/Earnings | 18.9x |
|
| Price/Sales | 3.1x |
|
| Price/Book | 2.7x |
|
| Price/Cash Flow | 20.8x |
|
| TEV/Sales | 3.0x |
|
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact NOVARTIS AG-ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.







